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Non-mumps Viral Parotitis During the 2014–2015
Influenza Season in the United States
Lina I. Elbadawi,1,2 Pamela Talley,1,3 Melissa A. Rolfes,1,4 Alexander J. Millman,1,4 Erik Reisdorf,5 Natalie A. Kramer,4 John R. Barnes,4 Lenee Blanton,4
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Anna Kocharian,2 Daniel Leifer,4 Karen Martin,3 Lisa McHugh,11 Rebecca J. McNall,12 Jennifer Palm,3 Kay W. Radford,12 Sara Robinson,13
Jennifer B. Rosen,8 Senthilkumar K. Sakthivel,12 Peter Shult,5 Anna K. Strain,3 George Turabelidze,14 Lori A. Webber,13 Meghan Pearce Weinberg,1,6
David E. Wentworth,4 Brett L. Whitaker,12 Lyn Finelli,4 Michael A. Jhung,4 Ruth Lynfield,3 and Jeffrey P. Davis2,†
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(See the Major Article by Rolfes et al on pages 485–92 and the Editorial Commentary by Pavia on pages 502–3.)
Background. During the 2014–2015 US influenza season, 320 cases of non-mumps parotitis (NMP) among residents of 21
states were reported to the Centers for Disease Control and Prevention (CDC). We conducted an epidemiologic and laboratory
investigation to determine viral etiologies and clinical features of NMP during this unusually large occurrence.
Methods. NMP was defined as acute parotitis or other salivary gland swelling of >2 days duration in a person with a mumpsnegative laboratory result. Using a standardized questionnaire, we collected demographic and clinical information. Buccal samples
were tested at the CDC for selected viruses, including mumps, influenza, human parainfluenza viruses (HPIVs) 1–4, adenoviruses,
cytomegalovirus, Epstein-Barr virus (EBV), herpes simplex viruses (HSVs) 1 and 2, and human herpes viruses (HHVs) 6A and 6B.
Results. Among the 320 patients, 65% were male, median age was 14.5 years (range, 0–90), and 67% reported unilateral parotitis. Commonly reported symptoms included sore throat (55%) and fever (48%). Viruses were detected in 210 (71%) of 294 NMP
patients with adequate samples for testing, ≥2 viruses were detected in 37 samples, and 248 total virus detections were made among
all samples. These included 156 influenza A(H3N2), 42 HHV6B, 32 EBV, 8 HPIV2, 2 HPIV3, 3 adenovirus, 4 HSV-1, and 1 HSV-2.
Influenza A(H3N2), HHV6B, and EBV were the most frequently codetected viruses.
Conclusions. Our findings suggest that, in addition to mumps, clinicians should consider respiratory viral (influenza) and herpes viral etiologies for parotitis, particularly among patients without epidemiologic links to mumps cases or outbreaks.
Keywords. non-mumps viral parotitis; non-mumps parotitis; parotitis.
Acute, viral non-mumps parotitis (NMP) is an infrequently
recognized illness that occurs sporadically and has been associated with multiple etiologic agents, including adenoviruses,
enteroviruses (coxsackieviruses, echoviruses), Epstein-Barr
virus (EBV), human herpes virus (HHV) 6A and 6B, influenza
A(H3N2) and influenza B viruses, human parainfluenza viruses
(HPIVs) 1–3, and parvovirus B-19 [1–9]. While there is no
systematic surveillance for NMP, results of several studies have
suggested EBV is the most frequently detected virus among
patients with NMP, followed by HPIV3, HPIV2, and adenoviruses [6–9]. During January 2015, approximately 17 cases
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of NMP were reported to the Centers for Disease Control and
Prevention (CDC) from several Midwestern states. Although
small in number, these temporally related reports represented
an unusual occurrence of viral NMP.
The only known cause of epidemic parotitis among humans is
mumps, a vaccine-preventable disease caused by mumps virus,
a member of the Rubulavirus genus of the Paramyxoviridae
family [10]. Prior to the licensure of mumps vaccine in 1967
and its subsequent routine use in the United States, mumps
was one of the most frequently reported diseases during
childhood [11, 12]. Since 1990, the Advisory Committee on
Immunization Practices to the CDC has recommended children routinely receive 2 doses of measles–mumps–rubella vaccine (MMR) [13]; the effectiveness against mumps following
2 doses of MMR is approximately 88% (range, 66%–95%) [14,
15]. This vaccine recommendation had a powerful impact on
reducing mumps occurrence from more than 150 000 cases
reported annually during the 1960s to a nadir of approximately
250 cases reported annually during 2000–2005 [16].

Non-mumps Viral Parotitis in the United States • CID 2018:67 (15 August) • 493

Downloaded from https://academic.oup.com/cid/article/67/4/493/4957004 by guest on 12 October 2021

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Bureau of Communicable Diseases, Wisconsin Division of Public Health, Madison; 3Minnesota
Department of Health, St. Paul; 4Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia; 5Wisconsin State Laboratory of Hygiene, Madison; 6Michigan Department of
Health and Human Services, Lansing; 7New Hampshire Division of Public Health Services, Concord; 8New York City Department of Health & Mental Hygiene Bureau of Immunization, Queens;
9
CSTE/CDC Applied Epidemiology Fellowship, Atlanta, Georgia; 10Children’s Mercy Hospital, Kansas City, Missouri; 11Communicable Disease Service, New Jersey Department of Health, Trenton;
12
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 13Maine Center for Disease Control and Prevention, Maine Department of Health and Human Services,
Augusta; and 14Missouri Department of Health and Senior Services, St. Louis

RT-PCR or viral culture) or had a buccal swab specimen available for viral testing at the CDC. Surveillance methods for eligible patients varied among states; methods included contacting
clinicians using the Health Alert Network, using clinician email
listservs, enhancing existing influenza surveillance activities, and
passive reporting of suspected mumps cases.
Case ascertainment and investigation were designated as
public health surveillance and were given a nonresearch determination by a CDC institutional review board. A questionnaire
was administered by telephone to consenting eligible persons or
their guardians. Information collected included patient demographic information; signs and symptoms; testing for mumps,
influenza, and other viral agents; past medical history; selfreported current and previous seasonal influenza vaccination;
self-report of MMR vaccination; hospitalization during the past
12 months; and recent travel.

METHODS

The real-time RT-PCR assays to detect mumps RNA were performed as previously described [19].

Case Ascertainment and Epidemiologic Investigation

On 22 December 2014, the CDC’s Influenza Division was
notified by the Indiana State Department of Health of a cluster of patients with influenza-associated parotitis. On 9 January
2015, after additional state health departments reported similar
occurrences of viral NMP, the Influenza Division notified state
and local health departments of the occurrence of influenzaassociated parotitis through the Epidemic Information
Exchange and requested notification when a patient with nonmumps parotitis associated with influenza was identified and
the illness met the case definition [18]. On 4 February, state
and local health departments and public health laboratories
were invited to participate in a multistate investigation of NMP.
States could participate in the case-control study of influenza-associated parotitis and/or the epidemiologic and laboratory
investigation of NMP regardless of etiology. The methods and
results of the case-control study are presented elsewhere [18].
For the epidemiologic and laboratory investigation of NMP, a
case was defined as clinical signs or symptoms compatible with
acute parotitis or other salivary gland swelling of >2 days duration in a patient with illness onset from 1 October 2014 through
31 May 2015, who had no known epidemiologic linkage to a laboratory-confirmed case of mumps, did not have a laboratory-confirmed diagnosis of mumps infection (was either mumps-negative
or not tested for mumps), and either had a laboratory-confirmed
non-mumps viral infection (using a recommended test, including
494 • CID 2018:67 (15 August) • Elbadawi et al

Laboratory Testing and Analysis

The CDC Division of Viral Disease laboratories conducted testing for mumps virus, HPIV 1–4, adenoviruses, and herpes family
viruses, including cytomegalovirus (CMV), EBV, herpes simplex
virus (HSV) 1 and 2, HHV6A, and HHV6B. The CDC Influenza
Division laboratories conducted testing for influenza viruses.
Mumps Virus

Herpes Family Viruses

HHV6

A conventional PCR method coupled with gel electrophoresis
was used to screen samples for the presence of HHV6. The primers are from the immediate early gene, U90, and are designed
to discriminate HHV6A from HHV6B based on a deletion in
the U1102 strain. HHV6A-positive samples are determined by
a band size of 325 bp; whereas a band size of 553 bp is the result
for HHV6B-positive samples [7, 20].
EBV

Specimens were screened using a real-time florescence resonance energy transfer (FRET)–based PCR method that uses 2
florescent probes, the anchor and the detector. When the target is
present, these bound probes are in close proximity and release a
detectable signature florescence. The target for this method is the
BamHI region of EBV [7].
HSV1/2

FRET technology was used to discriminate HSV-1 from HSV-2
in this real-time PCR method targeting the glycoprotein B,
UL27, gene. This 2-probed system can discriminate type 1 from
type 2 based on melt curve analysis. A sample is considered
HSV-1 positive if the melt temperature (Tm) is 56°C and HSV-2
positive if the Tm is 63°C (CDC, unpublished method).
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Laboratory testing includes serologic assays to detect mumps
immunoglobulin M (IgM), virus culture, or conventional or
real-time reverse transcription polymerase chain reaction
(RT-PCR) to detect mumps viral RNA. However, confirming
mumps virus infection can be challenging among persons with
immunity induced by prior vaccination or infection. Upon
infection, patients with prior immunity may not mount an IgM
response or may have low viral load, thus a negative RT-PCR or
serologic test result does not rule out mumps in a patient with
compatible signs and symptoms [17].
Because of the unusual occurrence of viral NMP during the
2014–2015 influenza season and the importance of pursuing laboratory confirmation when acute parotitis occurs and mumps is
suspected, enhanced understanding of the epidemiologic and clinical features of acute NMP would improve the accuracy of diagnosis among clinicians evaluating suspected mumps cases and result
in more timely treatment and public health action when appropriate. During February 2015, we initiated a multistate epidemiologic and laboratory study to describe the etiologic, demographic,
epidemiologic, and clinical features of all reported cases of NMP
and a parallel multistate case-control study to examine risk factors
for the occurrence of NMP caused by influenza A(H3N2) viruses
that circulated during the 2014–2015 season. Here, we present the
results of the epidemiologic and laboratory study.

Influenza Viruses

Influenza virus infection was confirmed and typed/subtyped
using RT-PCR with standard protocols or next-generation
sequencing. RT-PCR assays to detect influenza viral RNA were
performed as previously described [21] or next-generation
sequencing was conducted using a MiSeq platform and the
Iterative Refinement Meta Assembler [22]. Study sequences
were compared to viral reference sequences and sequences from
other circulating viruses.
Adenoviruses and Human Parainfluenza Viruses 1–4

Statistical Analyses

2
Statistical analyses included use of χ test to compare proportions and Wilcoxon rank-sum tests to compare medians.
Analyses were performed with SAS® version 9.3 (SAS Institute,
Cary, NC).

RESULTS
Virus Detections

From 1 October 2014 through 31 May 2015, 323 cases of NMP
among residents of 21 states were reported to the CDC. The
geographic distribution of viruses detected during testing at the
CDC of buccal samples from 294 NMP patients from 19 states
is summarized in Figure 1 and Table 1. Influenza A(H3N2)
virus was detected in 156 (53%) patient samples, including
≥1samples from all 19 states with reported cases. HHV6B was

Patient Characteristics

Data regarding demographic and clinical features and exposure and vaccination history from 320 NMP patients (with
sufficient data) are summarized in Tables 2–4. Among these
patients, most were male (65%), median age was 14.5 years
(range, <1–90; [interquartile range (IQR), 8–30 years]), and
64% were aged <20 years (Table 2). There were significant differences in sex and median age by virus detection category,
which includes single virus detected in the sample (4 categories: influenza A(H3N2), other respiratory viruses, HHV6B,
and EBV), virus codetection, and no virus detected (Table 2).
The percentage male was greatest among patients with influenza virus single detections and codetections (32 of 37 codetections included influenza virus) and least among patients
with no virus detected. Younger median age was associated
with HHV6B detection, other respiratory virus detection
(HPIV2/3 and adenovirus), and virus codetection, while older
median age was associated with EBV and no virus detected
(Table 2).
Among the 294 patients with buccal samples tested, 232 (79%)
were aged 5–49 years. Single detections of influenza A(H3N2)
virus occurred in all age groups, but 76 (61%) occurred among
patients aged 5–19 years (Figure 2). Among single detections
of other viruses, 14 (74%) HHV6B detections and all other
respiratory virus detections occurred among younger patients
(aged <14 years), and 14 (78%) EBV detections occurred among

Figure 1. Geographic distribution of viruses detected among patients with non-mumps viral parotitis, with samples tested at the Centers for Disease Control and Prevention,
United States, 1 October 2014–31 May 2015. Abbreviations: EBV, Epstein-Barr virus; HHV, human herpes virus; HPIV, human parainfluenza virus; HSV, herpes simplex virus.
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Sample nucleic acid extracts were tested using CDC singleplex
real-time RT-PCR assays for adenoviruses and parainfluenza
types 1–4 [23]. Threshold cycle values were determined by manually adjusting the fluorescence baseline to fall within the exponential phase of the amplification curves and above any background
signal. A positive test result was considered a well-defined curve
that crossed the threshold cycle within 40 cycles.

detected in 42 (14%) samples from 10 states. Six other viruses
were detected, including adenovirus (1%), HPIV2 (3%), HPIV3
(0.7%), EBV (13%), HSV-1 (1.4%), and HSV-2 (0.3%), primarily in specimens from Midwestern and Northeastern states
(Table 1). Multiple viruses were detected in 13% of samples.
Mumps virus, CMV, HHV6A, HPIV1, and HPIV4 were not
detected in any sample.

Table 1. Viruses Detected in Samples from Patients With Non-mumps Viral Parotitis Tested at the Centers for Disease Control and Prevention and
Number of Detections by Virus and State, United States, 1 October 2014–31 May 2015

Adenovirus (N = 3)

HPIV2 (N = 8)

HPIV3 (N = 2)

HHV6B
(N = 42)

EBV (N = 32)

HSV1
(N = 4)

HSV2 (N = 1)

California

4

0

0

0

0

0

0

0

Indiana

1

1

1

0

0

0

0

1

Maine

3

0

0

0

3

0

0

0

Massachusetts

3

0

0

0

0

0

0

0

Michigan

10

0

0

0

2

2

0

0

Minnesota

71

0

3

2

17

16

4

0

Missouri

5

0

0

0

1

0

0

0

New Hampshire

6

0

1

0

2

1

0

0

New Jersey

4

0

0

0

0

0

0

0

New Yorka

4

1

2

0

9

9

0

0

North Carolina

1

1

0

0

0

0

0

0

Oregon

1

0

0

0

1

1

0

0

Pennsylvania

5

0

0

0

0

0

0

0

South Carolina

2

0

0

0

1

0

0

0

Texas

4

0

0

0

0

0

0

0

Virginia

4

0

0

0

1

0

0

0

Washington

1

0

0

0

0

0

0

0

West Virginia

2

0

0

0

0

0

0

0

25

0

1

0

5

3

0

0

State

Wisconsin

Abbreviations: EBV, Epstein-Barr virus; HHV, human herpes virus; HPIV, human parainfluenza virus; HSV, herpes simplex virus.
Two viruses were codetected in each of 36 samples. The codetection pairings included 19 samples with influenza A(H3N2) virus and HHV6B detected, 10 with influenza A(H3N2) virus and
EBV, 2 with EBV and HHV6B, 2 with influenza A(H3N2) virus and HSV-1, 1 with EBV and HPIV2, 1 with HHV6B and HPIV2, and 1 with HPIV2 and HSV-2. Three viruses were detected in 1
sample: influenza A(H3N2) virus, EBV, and HHV6B. Eighty-four samples from patients with non-mumps parotitis that were tested at the Centers for Disease Control and Prevention had no
viruses detected. These samples were from patients from 8 states: Indiana, 1; Michigan, 2; Minnesota, 38; New Hampshire, 1; New York, 20 (19 from New York City and 1 from New York
State); Texas, 1; Virginia, 1; and Wisconsin, 20.
a

Represents New York City (36 samples) and New York State (9 samples).

older patients (aged >19 years). Among patients with no virus
detected, 47 (56%) were aged >19 years (Figure 2, Table 2).
Among all patients, 67% reported unilateral parotitis and 40%
reported influenza-like illness (ILI; fever [temperature ≥100oF]
or feeling feverish and cough or sore throat). Unilateral parotitis
was less frequent among patients with no virus detected. Patients
with influenza virus detection more frequently reported ILI and
other symptoms preceding parotitis onset than patients with
EBV or no virus detected (Tables 2 and 3). Among all patients,
46% reported receiving antibiotics during their illnesses; with
the exception of patients with EBV detection, little difference
in percentage with antibiotic receipt was noted by virus detection category (Table 2). Among all patients, 5% reported complications and 11% were hospitalized; hospitalization was most
frequent (22%) among patients with EBV detection, although
numbers were small.
Most samples (69%) were collected within 2 days after parotitis onset. Specimens with no viruses detected were more likely
to be collected >2 days after parotitis onset than specimens with
viruses detected (Table 3).
Overall, 141 (44%) patients reported having an underlying medical condition, and asthma (23%) and obesity (18%)
were the most common reported conditions. There was little
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difference in frequency of underlying conditions by virus detection category (Table 4).
There was little difference in history of mumps virus infection,
parotitis, respiratory syncytial virus infection, or mononucleosis during the past year by virus detection category (Table 4).
History of strep throat during the past year was more frequently
reported among patients with virus codetection, although numbers were small (Table 4). Prior hospitalization during the past
year was more frequent among patients with EBV detection.
Except for lower frequency of MMR vaccination among
patients with EBV detected, there were no significant differences in MMR or influenza vaccination history by virus detection category (Table 4).
DISCUSSION

We report the largest known survey of sporadic cases of NMP
and influenza-associated NMP, including 294 patients with
interviews and sufficient samples available for further testing. Influenza viruses and viruses in the herpes family were
commonly detected among these patients. All illness onsets
occurred during the 2014–2015 US influenza season (October–
May). Eight viruses were detected, and 210 (71%) of the samples tested were positive for at least 1 virus. The most frequently
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Influenza A(H3N2)
Virus
(N = 156)

Table 2. Demographic Features, Self-reported Signs and Symptoms, and Other Clinical Characteristics Among 320 Patients With Non-mumps
Parotitis by Virus Detection Category, United States, 1 October 2014–31 May 2015

Variable

Total Non-Mumps
Parotitis (N = 320)

Influenza A(H3N2)
Virusa
(N = 124)

Other Respiratory
Virusa,b
(N = 10)

Virus Codetectionc
(N = 37)

Human Herpes
Virus 6Ba
(N = 19)

Epstein-Barr
Virusa (N = 18)

No Virus
Detected
(N = 84)

92 (75)e

5 (50)

27 (73)

12 (63)

10 (56)

43 (51)e

Demographic features, n (%)d
Male
Age, median years
Range
Interquartile range

207 (65)

f

f

f

f

14.5

14

7

10

5

35

26f

<1–90

<1–84

1–12

2–77

<1–37

<1–90

1–74

8–30

8–23

6–8

6–18

2–9

16–60

11–40

Self-reported signs and symptoms, n (%)d
129 (40)

64 (52)e

3 (30)

13 (35)

5 (26)

4 (22)

23 (27)

Fever/feverishi

153 (48)

73 (59)e

6 (60)

14 (38)

5 (26)

5 (28)

33 (39)

Chills

116 (38)

56 (45)

8 (80)

13 (35)

4 (21)

5 (28)

24 (29)

Muscle ache

100 (31)

40 (33)

4 (40)

9 (24)

2 (11)

4 (22)

28 (33)

Headache

124 (39)

49 (40)

5 (50)

15 (41)

3 (16)

5 (28)

13 (15)

Cough

118 (37)

62 (50)

4 (40)

19 (51)

4 (21)

3 (16)

11 (13)

39 (12)

17 (14)

2 (20)

4 (11)

1 (5)

2 (11)

8 (10)

177 (55)

67 (55)

4 (40)

18 (49)

9 (47)

5 (29)

47 (56)

98 (31)

37 (30)

5 (50)

17 (46)

1 (6)

2 (11)

18 (21)

121 (38)

46 (37)

6 (60)

7 (19)

10 (53)

5 (29)

34 (40)

Wheeze
Sore throat
Runny nose
Ear pain
Rash

24 (8)

8 (7)

0 (0)

3 (8)

4 (21)

1 (6)

5 (6)

Facial swelling

239 (75)

97 (79)

7 (70)

28 (76)

11 (58)

15 (83)

62 (74)

Gland swelling

213 (67)

80 (65)

4 (40)

26 (70)

11 (58)

10 (56)

61 (73)

Unilateral parotitis

215 (67)

84 (68)

7 (70)

29 (78)

16 (84)

11 (61)

49 (58)e

91 (28)

37 (30)

2 (20)

6 (16)

2 (11)

7 (39)

28 (33)

Hospitalized during
illness

34 (11)

9 (7)

1 (10)

5 (14)

2 (11)

4 (22)e

9 (11)

Experienced complication from illnessg

16 (5)

3 (3)

0 (0)

3 (9)

0 (0)

1 (6)

7 (8)

Received antibiotics
during illness

150 (46)

62 (50)

4 (40)

16 (43)

8 (42)

5 (28)

40 (48)

Bilateral parotitis
Clinical characteristics, n (%)d

Included are 210 patients with non-mumps parotitis (NMP) who had buccal specimens from which 1 or more viruses were detected. These patients were subsequently defined as having
non-mumps viral parotitis. Also included are 84 patients with NMP who had specimens from which viruses were not detected.
a

Unless otherwise noted, virus detection indicates single detections of a virus in a sample.

b

Other respiratory viruses include human parainfluenza virus 2 (HPIV2) detected in 5 samples, HPIV3 detected in 2 samples, and adenovirus detected in 3 samples.

c

Two viruses were codetected in each of 36 samples. The codetection pairings included 19 samples with influenza A(H3N2) virus and human herpes virus 6B (HHV6B) detected, 10 with
influenza A(H3N2) virus and Epstein-Barr virus (EBV), 2 with EBV and HHV6B, 2 with influenza A(H3N2) virus and herpes simplex virus-1 (HSV-1), 1 with EBV and HPIV2, 1 with HHV6B and
HPIV2, and 1 with HPIV2 and HSV-2. Three viruses were detected in 1 sample: influenza A(H3N2) virus, EBV, and HHV6B.
d

Unless otherwise noted.
2
The χ test P value < .05. Reference group consists of patients not in the category; for example, patients with HHV6B detected were compared with patients with samples in which HHV6B
was not detected.
e

f
Wilcoxon rank-sum test P value < .05. Reference group consists of patients not in the category; for example, patients with HHV6B detected were compared with patients with samples
in which HHV6B was not detected.
g

Self-reported complications included ear infections, testicular pain, pneumonia, and abdominal pain.

h

Influenza-like illness defined as fever (temperature ≥100oF) or feeling feverish and cough or sore throat.

i

Temperature ≥100oF or self-report of feeling feverish.

detected viruses were influenza A(H3N2), 156 detections in
patients from 19 states; HHV6B, 42 detections; and EBV, 32
detections. Codetections of influenza A(H3N2) virus with
HHV6B or EBV viruses were also common.
Investigators in other Northern Hemisphere countries have
also reported on viral etiologies of NMP during the 2014–2015
influenza season [24–26]. While 2 of these investigations [25,
26] restricted their laboratory investigation to influenza viruses,
a survey in the United Kingdom tested children for a broad
panel of respiratory viruses, identifying influenza A(H3N2)

virus in 16 (15%) samples and respiratory syncytial virus A with
codetection of influenza A/H3 in 1 sample [26]. Similarly, we
found an increased occurrence of influenza A(H3N2) virus–
associated parotitis in this cohort, which might be an artifact of
enhanced surveillance and case-finding efforts or a reflection of
the dominance of influenza A(H3N2) virus in North America
and Europe during the 2014–2015 season [27].
When included in the test panels, EBV was the most frequently detected virus in studies investigating etiologies of
NMP prior to the 2014–2015 influenza season. Among 5
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Influenza-like illnessh

such studies, the average EBV detection rate was 20% (range,
6%–25%); however, EBV test methods varied [6–9, 28, 29]. We
detected EBV in 13% of samples; however, the lower frequency
reported here might have resulted from the initial surveillance
focus on influenza-associated NMP.

The second most commonly detected virus among patients
tested during this 2014–2015 study was HHV6B. Investigators in
the United States and Finland screened patients with NMP during 2009–2011 and 1993–1998 for HHV6, respectively, with comparable results [7, 8]. The US study used a PCR-based molecular

Table 3. Timing of Sample Collection and Symptom Onset Among 320 Patients With Non-mumps Parotitis by Virus Detection Category, United
States, 1 October 2014–31 May 2015

Variable

Total NonHuman Herpes
Influenza A(H3N2)
Other Respiratory Virus Codetectionc
Epstein-Barr
No Virus
Mumps Parotitis
Virus 6Ba
Virusa
a,b
(N = 124)
Virus (N = 10)
(N = 19)
Virusa (N = 18) Detected (N = 84)
(N = 37)
(N = 320)

Timing of sample collection, n (%)d
≤2 days after any
symptom onset

148 (46)

48 (39)

4 (40)

14 (38)

12 (63)

13 (72)

37 (44)

≤2 days after parotitis
onset

222 (69)

89 (72)

7 (70)

29 (78)

14 (74)

13 (72)

44 (52)e

Symptom onset preceded
parotitis onset

154 (55)

71 (63)e

5 (50)

23 (62)

6 (32)

4 (27)e

24 (29)e

Symptom onset at same
time as parotitis onset

106 (38)

38 (34)

3 (20)

8 (22)

6 (32)

7 (47)

38 (45)

Parotitis onset preceded
other symptom onset

8 (3)

0 (0)

2 (20)

0 (0)

0 (0)

2 (13)

5 (6)

Timing of symptom onset, n (%)d

Included are 210 patients with non-mumps parotitis (NMP) who had buccal specimens from which 1 or more viruses were detected. These patients were subsequently defined as having
non-mumps viral parotitis. Also included are 84 patients with NMP who had specimens from which viruses were not detected.
a

Unless otherwise noted, virus detection indicates single detections of a virus in a sample.

b

Other respiratory viruses include human parainfluenza virus 2 (HPIV2) detected in 5 samples, HPIV3 detected in 2 samples, and adenovirus detected in 3 samples.

c

Two viruses were codetected in each of 36 samples. The codetection pairings included 19 samples with influenza A(H3N2) virus and human herpes virus 6B (HHV6B) detected, 10 with
influenza A(H3N2) virus and Epstein-Barr virus (EBV), 2 with EBV and HHV6B, 2 with influenza A(H3N2) virus and herpes simplex virus 1(HSV-1), 1 with EBV and HPIV2, 1 with HHV6B and
HPIV2, and 1 with HPIV2 and HSV-2. Three viruses were detected in 1 sample: influenza A(H3N2) virus, EBV, and HHV6B.
d

Unless otherwise noted.
2
The χ test P value < .05. Reference group consists of patients not in the category; for example, patients with samples in which HHV6B detected were compared with patients with samples
in which HHV6B was not detected.
e
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Figure 2. Virus detection among patients with non-mumps parotitis by age group, United States, 1 October 2014–31 May 2015. * Unless otherwise noted, virus detection
indicates single detections of a virus in a sample. †Two viruses were codetected in each of 36 samples. The codetection pairings included 19 samples with influenza A(H3N2)
virus and human herpes virus 6B (HHV6B) detected, 10 with influenza A(H3N2) virus and Epstein-Barr virus (EBV), 2 with EBV and HHV6B, 2 with influenza A(H3N2) virus and
herpes simplex virus1 (HSV-1), 1 with EBV and human parainfluenza virus 2 (HPIV2), 1 with HHV6B and HPIV2, and 1 with HPIV2 and HSV-2. Three viruses were detected in 1
sample: influenza A(H3N2) virus, EBV, and HHV6B. ‡ Other respiratory viruses include HPIV2 detected in 5 samples, HPIV3 detected in 2 samples, and adenovirus detected in
3 samples. Abbreviations: EBV, Epstein-Barr virus; HHV, human herpes virus.

Table 4. Underlying Medical Conditions, Exposure History, and Vaccination History Among Patients With Non-mumps Parotitis and Non-mumps
Viral Parotitis by Virus Detection Category, United States, 1 October 2014–31 May 2015

Variable

Human
Herpes Virus
6Ba
(N = 19)

Total Non-Mumps
Parotitis (N = 320)

Influenza
A(H3N2)a
(N = 124)

Other Respiratory
Virusa,b (N = 10)

Virus Codetectionc
(N = 37)

141 (44)

61 (50)

4 (40)

11 (30)

3 (16)e

8 (44)

40 (48)

72 (23)

29 (24)

4 (40)

5 (14)

2 (11)

4 (22)

21 (25)

7 (2)

2 (2)

0 (0)

1 (3)

0 (0)

2 (11)

1 (1)

Epstein-Barr
Virusa (N = 18)

No Virus
Detected
(N = 84)

Underlying medical condition, n (%)d
Had any underlying medical condition
Asthma
Chronic obstructive pulmonary disease or chronic lung condition
Cardiovascular condition

13 (4)

6 (5)

0 (0)

1 (3)

0 (0)

0 (0)

2 (2)

Diabetes

14 (4)

4 (3)

0 (0)

2 (5)

1 (5)

2 (11)

4 (5)

Renal condition

3 (0.9)

1 (0.8)

0 (0)

0 (0)

0 (0)

0 (0)

1 (1)

Immunosuppressive condition

7 (2)

3 (3)

0 (0)

0 (0)

0 (0)

0 (0)

2 (2)

5 (2)

3 (3)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

13 (4)

8 (7)

0 (0)

0 (0)

0 (0)

0 (0)

3 (4)

Rheumatoid arthritis

8 (3)

2 (2)

0 (0)

1 (3)

0 (0)

0 (0)

4 (5)

Sjogren’s syndrome

2 (0.6)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (1)

Obesity

55 (18)

20 (17)

0 (0)

5 (14)

2 (11)

2 (11)

20 (24)

Other conditionf

16 (5)

6 (5)

0 (0)

0 (0)

0 (0)

2 (11)

8 (10)

Exposure history, n (%)d
History of mumps virus infection

19 (6)

3 (3)

0 (0)

5 (14)

0 (0)

2 (11)

8 (10)

History of parotitis

18 (6)

2 (2)

0 (0)

3 (9)

1 (6)

2 (11)

7 (8)

Strep throat in past year

41 (13)

22 (18)

3 (30)

1 (3)e

3 (16)

1 (6)

10 (12)

0 (0)

0 (0)

0 (0)

0 (0)

2 (11)

0 (0)

Respiratory syncytial virus or mononucleosis in past year

2 (0.6)

Hospitalization for other illness in
past year

26 (8)

8 (7)

1 (10)

3 (8)

0 (0)

5 (28)e

1 (1)

Dentist/oral surgeon visit within 2
weeks before illness

8 (3)

3 (2)

0 (0)

1 (3)

0 (0)

0 (0)

3 (4)

Sinus procedure within 2 weeks before illness

1 (0.3)

1 (0.8)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Aware of others with parotitis/mumps

44 (14)

6 (5)

0 (0)

4 (12)

1 (11)

2 (11)

10 (12)

Travel within 2 weeks before illness

24 (8)

19 (16)

2 (20)

4 (12)

2 (6)

1 (6)

11 (13)

Vaccination history, n (%)d
Influenza vaccine: 2013–2014 season

195 (62)

84 (69)

7 (70)

21 (58)

10 (53)

11 (61)

45 (54)

Influenza vaccine: 2014–2015 seasong

179 (56)

67 (55)

5 (50)

18 (49)

14 (74)

10 (56)

47 (56)

Measles–mumps–rubella vaccinationh

280 (89)

113 (93)

10 (100)

33 (89)

18 (95)

11 (61)e

69 (82)

a

Unless otherwise noted, virus detection indicates single detections of a virus in a sample.

b

Other respiratory viruses include human parainfluenza virus 2 (HPIV2) detected in 5 samples, HPIV3 detected in 2 samples, and adenovirus detected in 3 samples.

c

Two viruses were codetected in each of 36 samples. The codetection pairings included 19 samples with influenza A(H3N2) and human herpes virus 6B (HHV6B) detected, 10 with influenza
A(H3N2) and Epstein-Barr virus (EBV), 2 with EBV and HHV6B, 2 with influenza A(H3N2) and herpes simplex virus 1 (HSV-1), 1 with EBV and HPIV2, 1 with HHV6B and HPIV2, and 1 with
HPIV2 and HSV-2. Three viruses were detected in 1 sample: influenza A(H3N2), EBV, and HHV6B.
d

Unless otherwise noted.

e

The χ2 test P value < .05. Reference group consists of patients not in the category; for example, patients with HHV6B detected were compared with patients with samples in which HHV6B
was not detected.
f

Other conditions included hepatic disease.

g

Received influenza vaccine at least 2 weeks before symptom onset.

h

Reported receiving at least 1 dose of the measles–mumps–rubella vaccine.

assay, while the Finnish study used a serologic assay; the HHV6B
detection rate was 4%–10%. In the US study, the median age of
patients with HHV6B detection was 6 years (range, 0–35), while
testing for HHV6 was limited to children aged <4 years in the
Finnish study. In our investigation, patients who had NMP with
HHV6B had an age distribution similar to the range in the prior
US study and were predominately male. HHV6 is found to infect
almost all individuals during early childhood and, similar to
other herpes viruses, is capable of reactivation in both normal

and immunocompromised persons [30]. Interestingly, HHV6
appears to persist in salivary glands and viral DNA can be routinely detected in saliva using PCR [30]. Furthermore, HHV6B
is the predominant strain found in both normal and immunocompromised hosts, which might explain the high frequency of
HHV6B detection in our case series.
Of note, our rate of codetection of viruses in patient samples
was 14%, and each of the 37 codetection samples included a herpes virus (HHV6B, EBV, HSV1, or HSV2) with either a respiratory
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Chemotherapy in past year
Neurologic/neurodevelopmental
condition
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In conclusion, we investigated a large occurrence of nonmumps parotitis during the 2014–2015 US influenza season.
Possible viral etiologic agents other than mumps virus were
detected in a high proportion of samples tested. These detections resulted, in part, from enhanced surveillance, including
additional respiratory testing at state public health laboratories
and active case-finding efforts. To correctly exclude mumps
virus as the etiology of parotitis with mumps-negative RT-PCR
results, obtaining additional NP swabs for viral testing within
2 days of parotitis onset should also be considered, particularly
among patients without epidemiologic links to mumps cases or
outbreaks. Testing for illnesses that mimic mumps might result
in more timely and appropriate treatment, including antibiotic
cessation and public health response. Additional investigations
of NMP are warranted to better understand the etiologic, clinical, and epidemiologic features of outbreak-related and sporadically occurring cases.
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virus (influenza A(H3N2) virus, 32 samples or HPIV2, 3 samples)
or another herpes virus (2 samples). Results of 1 study included
codetection with EBV and respiratory viruses [9]; another
reported codetection with respiratory viruses, with codetection
rates ranging from 2% to 8% [6]. Results of prior studies suggest
that infection with influenza and other respiratory viruses might
reactivate herpes family viruses [31, 32]. In our study, patients with
codetections did not report higher frequency of complications,
hospitalizations, or underlying medical conditions compared with
patients having samples with single virus detection.
It is challenging to determine the etiologic agents among sporadic cases of parotitis occurring in regions with a low incidence
of mumps. Information regarding parotitis onset and timing of
sample collection is important when interpreting laboratory
results. In our study, 69% of oral samples were collected during the first 2 days following parotitis onset; among those samples, viruses were detected in 156 (70%), and the most frequent
viruses detected were influenza A(H3N2) virus, HHV6B, and
EBV. Further, detection of mumps virus by RT-PCR decreases
>2 days following onset of swelling independently of the vaccination status. In one study, the sensitivity of RT-PCR for
mumps virus detection decreased from 87% among oral samples collected during day 1 of swelling and 78% among samples
collected during day 2 to 41% among samples collected during day 3 [22]. To enhance detection and diagnostic accuracy
among patients with NMP, public health laboratories should
consider additional respiratory virus panel and herpes family
viral testing if resources permit.
Our investigation is subject to multiple limitations. First, it
did not include testing for bacterial causes and noninfectious
causes of parotitis, such as parotid stones [10]. This was intentional because the study focus was to characterize and describe
viral etiologies of NMP. Second, while buccal swab specimens
are the best diagnostic samples for suspected mumps, they are
less sensitive than nasopharyngeal (NP) swab specimens for
detection of respiratory viruses [33, 34]. This suboptimal sampling using buccal specimens might have resulted in an underestimation of the true prevalence of these viruses among our study
population. Third, detection of remnant genetic material from
previous infections could result in overestimation of the prevalence of certain viruses. Fourth, viruses that were not tested for,
including echoviruses and parvovirus B19, which are known but
rarely reported etiologies of viral NMP, potentially could have
contributed to clinical presentations among these patients. Fifth,
only samples associated with completed patient questionnaires
were analyzed. This might have resulted in underreporting of
certain viruses. Sixth, our initial case-finding strategy focused
on influenza-associated viral NMP. This might have resulted in a
higher-than-previously-reported occurrence of cases associated
with influenza A(H3N2) virus and a lower-than-previously-reported frequency of NMP cases associated with EBV.
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